PT - JOURNAL ARTICLE AU - Jolynne Mokaya AU - Anna L McNaughton AU - Phillip A Bester AU - Dominique Goedhals AU - Eleanor Barnes AU - Brian D. Marsden AU - Philippa C Matthews TI - Hepatitis B virus resistance to tenofovir: fact or fiction? A synthesis of the evidence to date AID - 10.1101/19009563 DP - 2019 Jan 01 TA - medRxiv PG - 19009563 4099 - http://medrxiv.org/content/early/2019/10/18/19009563.short 4100 - http://medrxiv.org/content/early/2019/10/18/19009563.full AB - Background Tenofovir (TFV) is a widely used antiviral treatment for chronic hepatitis B virus (HBV) infection. However, therapy is not curative and long-term administration is therefore required in most cases, with a risk of selecting resistance-associated mutations (RAMs). There is a high genetic barrier to the selection of TFV resistance, but the distribution and clinical significance of TFV RAMs are not well understood, and the topic remains contentious. We here present assimilated evidence for TFV RAMs with the aim of cataloguing and characterising mutations that are likely to be of most clinical significance, and starting to develop relevant mechanistic insights.Methods We carried out a systematic literature search in PubMed to identify clinical, in vitro and in silico evidence of TFV resistance. The structure of HBV reverse transcriptase (RT) has not been solved; we therefore compared HBV RT to the crystal structure for HIV RT in order to map the likely sites of RAMs.Results We identified 37 putative TFV RAMs in HBV RT, occurring within and outside sites of enzyme activity, which we have mapped onto a homologous HIV RT crystal structure. Most resistance arises as a result of suites of multiple RAMs. Other factors including adherence, HBV DNA viral load, HBeAg status, HIV coinfection and NA dosage may also influence viraemic suppression.Conclusion There is emerging evidence for polymorphisms that reduce susceptibility to TVF. If clinically significant TFV resistance increases in prevalence, there will be a pressing need for the development of new agents. A better understanding of HBV drug resistance is imperative to ensure that these do not impact on the international elimination targets that are to be met by 2030.LAY SUMMARY Tenofovir is the treatment of choice for chronic hepatitis B virus (HBV) infection because it has a low risk of resistance compared to other treatment available. However, we have assimilated the emerging evidence of HBV resistance to TDF, and we therefore advocate for the development of better treatment for chronic HBV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJM is funded by a Leverhulme Mandela Rhodes Scholarship. PCM is funded by the Wellcome Trust, grant number 110110. EB is funded by the Medical Research Council UK, the Oxford NIHR Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableData availability All data generated or analysed during this study are included in this published article (and its Supplementary Information files). https://figshare.com/s/7dcfa78cc5ed14094d6f 3TClamivudineADVAdefovirARTantiretroviral therapycccDNAcovalently closed circular DNACHBchronic hepatitis B virus infectionETVentecavir (ETV)HBsAgHepatitis B surface antigenHBVHepatitis b virusHIVhuman immunodeficiency virusLdTtelbivudineNANucleos(t)ide analogueRAMResistance Associated MutationRTreverse transcriptaseTAFtenofovir alafenamideTDFtenofovir disoproxil fumarateTFVtenofovir (the active component of both TAF and TDF)YMDDtyrosine methionine aspartate aspartate motif in HBV RT